1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
- 2014
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
-
Mark
Definitions in hemophilia: communication from the SSC of the ISTH
(
- Contribution to journal › Article
- 2013
-
Mark
Origin of Swedish hemophilia B mutations
(
- Contribution to journal › Article
-
Mark
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics, and preliminary efficacy in hemophilia patients with inhibitors.
(
- Contribution to journal › Article
- 2011
-
Mark
Modern treatment options for von Willebrand disease and haemophilia B - What are the benefits for the patients?
(
- Contribution to journal › Article
- 2010
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
Anti-prothrombin antibodies are associated with thrombosis in children.
(
- Contribution to journal › Article
- 2009
-
Mark
Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children.
(
- Contribution to journal › Article
- 2006
-
Mark
Are randomized clinical trials the only truth? Not always
(
- Contribution to journal › Debate/Note/Editorial